Drugs / BI 3812465
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07553429 | May 2026 → Mar 2027 expected | diabetic macular edema | Boehringer Ingelheim | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 3812465 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07553429 ↗ |
| Route | Intravitreal | “Multiple Rising Intravitreal Doses of BI 3812465” NCT07553429 ↗ |